• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

TONSL促进肺腺癌进展、免疫逃逸和药物敏感性。

TONSL promotes lung adenocarcinoma progression, immune escape and drug sensitivity.

作者信息

Liang Anru, Wu Zuotao, Zhuo Ting, Zhu Yongjie, Li Zihao, Chen Sirong, Dai Lei, Wang Yongyong, Tan Xiang, Chen Mingwu

机构信息

Department of Cardio-Thoracic Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, Guangxi, China.

Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.

出版信息

Clin Transl Oncol. 2025 Feb;27(2):518-533. doi: 10.1007/s12094-024-03627-w. Epub 2024 Aug 3.

DOI:10.1007/s12094-024-03627-w
PMID:39097545
Abstract

PURPOSE

The tonsoku-like DNA repair protein (TONSL) encoded by the TONSL gene, located on chromosome 8q24.3, is crucial for repairing DNA double-strand breaks through homologous recombination. However, TONSL overexpression in lung adenocarcinoma (LUAD) promotes tumor development, leading to a poor prognosis.

METHODS

TONSL was verified as a reliable prognostic marker for LUAD using bioinformatics, and clinical features related to LUAD prognosis were screened from the TCGA database to establish the relationship between risk factors and TONSL expression. In addition, TONSL expression in normal and LUAD tissues was verified using real-time quantitative polymerase chain reaction and immunohistochemistry. To elucidate the possible functions of TONSL, TONSL-related differentially expressed genes were screened, and functional enrichment analysis was performed. Subsequently, siRNA was used to knock down TONSL expression in lung cancer cells for cytobehavioral experiments. The effects of TONSL expression on tumor immune escape were analyzed using the ESTIMATE algorithm and tumor immune-infiltration analysis. In addition, the half-maximal inhibitory concentration of LUAD with varying TONSL expression levels in response to first-line chemotherapeutic drugs and epidermal growth factor receptor-tyrosine kinase inhibitors was analyzed for drug sensitivity.

RESULTS

Up-regulation of TONSL in LUAD promotes the proliferation, migration, and invasion of lung cancer cells, thereby contributing to a poor prognosis. Furthermore, TONSL overexpression promotes immune escape and drug sensitivity in LUAD.

CONCLUSION

TONSL serves as a reliable prognostic marker for LUAD, and its up-regulation is associated with increased immune escape and drug sensitivity. These findings suggest that TONSL holds potential as a novel therapeutic target for LUAD.

摘要

目的

位于染色体8q24.3的TONSL基因编码的类扁桃体DNA修复蛋白(TONSL)对于通过同源重组修复DNA双链断裂至关重要。然而,TONSL在肺腺癌(LUAD)中的过表达促进肿瘤发展,导致预后不良。

方法

使用生物信息学验证TONSL是LUAD的可靠预后标志物,并从TCGA数据库中筛选与LUAD预后相关的临床特征,以建立危险因素与TONSL表达之间的关系。此外,使用实时定量聚合酶链反应和免疫组织化学验证正常组织和LUAD组织中TONSL的表达。为了阐明TONSL的可能功能,筛选了与TONSL相关的差异表达基因,并进行了功能富集分析。随后,使用小干扰RNA(siRNA)敲低肺癌细胞中TONSL的表达以进行细胞行为实验。使用ESTIMATE算法和肿瘤免疫浸润分析来分析TONSL表达对肿瘤免疫逃逸的影响。此外,分析了不同TONSL表达水平的LUAD对一线化疗药物和表皮生长因子受体酪氨酸激酶抑制剂的半数最大抑制浓度,以评估药物敏感性。

结果

LUAD中TONSL的上调促进肺癌细胞的增殖、迁移和侵袭,从而导致预后不良。此外,TONSL过表达促进LUAD中的免疫逃逸和药物敏感性。

结论

TONSL是LUAD的可靠预后标志物,其上调与免疫逃逸增加和药物敏感性相关。这些发现表明TONSL有望成为LUAD的新型治疗靶点。

相似文献

1
TONSL promotes lung adenocarcinoma progression, immune escape and drug sensitivity.TONSL促进肺腺癌进展、免疫逃逸和药物敏感性。
Clin Transl Oncol. 2025 Feb;27(2):518-533. doi: 10.1007/s12094-024-03627-w. Epub 2024 Aug 3.
2
Malignant features related PRDX1 associated with osimertinib sensitivity of EGFR-mutant lung adenocarcinoma.与PRDX1相关的恶性特征与EGFR突变型肺腺癌的奥希替尼敏感性相关。
Int J Med Sci. 2025 Mar 31;22(9):2040-2058. doi: 10.7150/ijms.107255. eCollection 2025.
3
The role of EMG1 in lung adenocarcinoma progression: Implications for prognosis and immune cell infiltration.EMG1 在肺腺癌进展中的作用:对预后和免疫细胞浸润的影响。
Int Immunopharmacol. 2024 Sep 10;138:112553. doi: 10.1016/j.intimp.2024.112553. Epub 2024 Jun 28.
4
Down-regulation of KLRB1 is associated with increased cell growth, metastasis, poor prognosis, as well as a dysfunctional immune microenvironment in LUAD.KLRB1 的下调与 LUAD 中细胞生长增加、转移、预后不良以及功能失调的免疫微环境有关。
Sci Rep. 2024 May 23;14(1):11782. doi: 10.1038/s41598-024-60414-x.
5
Prognostic value and immune infiltration of a novel stromal/immune score-related P2RY12 in lung adenocarcinoma microenvironment.新型基质/免疫评分相关 P2RY12 在肺腺癌微环境中的预后价值及免疫浸润分析。
Int Immunopharmacol. 2021 Sep;98:107734. doi: 10.1016/j.intimp.2021.107734. Epub 2021 Jun 25.
6
FAM207BP, a pseudogene-derived lncRNA, facilitates proliferation, migration and invasion of lung adenocarcinoma cells and acts as an immune-related prognostic factor.FAM207BP,一个假基因衍生的长非编码 RNA,促进肺腺癌细胞的增殖、迁移和侵袭,并作为一个免疫相关的预后因素。
Life Sci. 2021 Mar 1;268:119022. doi: 10.1016/j.lfs.2021.119022. Epub 2021 Jan 9.
7
Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.肿瘤突变负荷与免疫浸润联合用于肺腺癌的预后评估。
Int Immunopharmacol. 2021 Sep;98:107807. doi: 10.1016/j.intimp.2021.107807. Epub 2021 Jun 25.
8
A nicotinamide metabolism-related gene signature for predicting immunotherapy response and prognosis in lung adenocarcinoma patients.一种用于预测肺腺癌患者免疫治疗反应和预后的烟酰胺代谢相关基因特征。
PeerJ. 2025 Feb 27;13:e18991. doi: 10.7717/peerj.18991. eCollection 2025.
9
Consensus clustering and novel risk score model construction based on m6A methylation regulators to evaluate the prognosis and tumor immune microenvironment of early-stage lung adenocarcinoma.基于 m6A 甲基化调控因子的共识聚类和新型风险评分模型构建,用于评估早期肺腺癌的预后和肿瘤免疫微环境。
Aging (Albany NY). 2024 Jul 5;16(14):11318-11338. doi: 10.18632/aging.206004.
10
NT5E (CD73) as a prognostic biomarker and therapeutic target associated with immune infiltration in lung adenocarcinoma.NT5E(CD73)作为与肺腺癌免疫浸润相关的预后生物标志物和治疗靶点。
Sci Rep. 2025 Feb 5;15(1):4340. doi: 10.1038/s41598-025-88964-8.

本文引用的文献

1
PD-1 inhibitor combined with Docetaxel exerts synergistic anti-prostate cancer effect in mice by down-regulating the expression of PI3K/AKT/NFKB-P65/PD-L1 signaling pathway.PD-1 抑制剂联合多西他赛通过下调 PI3K/AKT/NFKB-P65/PD-L1 信号通路的表达在小鼠中发挥协同抗前列腺癌作用。
Cancer Biomark. 2024;40(1):47-59. doi: 10.3233/CBM-230090.
2
Future Perspectives in the Second Line Therapeutic Setting for Non-Oncogene Addicted Non-Small-Cell Lung Cancer.非癌基因成瘾性非小细胞肺癌二线治疗的未来展望
Cancers (Basel). 2023 Nov 21;15(23):5505. doi: 10.3390/cancers15235505.
3
Scrambling the genome in cancer: causes and consequences of complex chromosome rearrangements.
在癌症中打乱基因组:复杂染色体重排的原因和后果。
Nat Rev Genet. 2024 Mar;25(3):196-210. doi: 10.1038/s41576-023-00663-0. Epub 2023 Nov 8.
4
Tumor mutation burden in the prognosis and response of lung cancer patients to immune-checkpoint inhibition therapies.肿瘤突变负荷在肺癌患者对免疫检查点抑制疗法的预后及反应中的作用
Transl Oncol. 2023 Dec;38:101788. doi: 10.1016/j.tranon.2023.101788. Epub 2023 Sep 28.
5
Cellular Therapy for Lung Cancer: Focusing on Chimeric Antigen Receptor T (CAR T) Cells and Tumor-Infiltrating Lymphocyte (TIL) Therapy.肺癌的细胞疗法:聚焦嵌合抗原受体T(CAR T)细胞和肿瘤浸润淋巴细胞(TIL)疗法。
Cancers (Basel). 2023 Jul 23;15(14):3733. doi: 10.3390/cancers15143733.
6
TONSOKU is required for the maintenance of repressive chromatin modifications in Arabidopsis.TONSOKU 对于拟南芥中抑制性染色质修饰的维持是必需的。
Cell Rep. 2023 Jul 25;42(7):112738. doi: 10.1016/j.celrep.2023.112738. Epub 2023 Jul 1.
7
TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer.TONSL 是乳腺癌中的永生化癌基因和治疗靶点。
Cancer Res. 2023 Apr 14;83(8):1345-1360. doi: 10.1158/0008-5472.CAN-22-3667.
8
Cancer statistics, 2023.癌症统计数据,2023 年。
CA Cancer J Clin. 2023 Jan;73(1):17-48. doi: 10.3322/caac.21763.
9
The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest.2023 年的 STRING 数据库:针对任何感兴趣的测序基因组的蛋白质-蛋白质关联网络和功能富集分析。
Nucleic Acids Res. 2023 Jan 6;51(D1):D638-D646. doi: 10.1093/nar/gkac1000.
10
The current state of the art and future trends in RAS-targeted cancer therapies.RAS 靶向癌症治疗的现状和未来趋势。
Nat Rev Clin Oncol. 2022 Oct;19(10):637-655. doi: 10.1038/s41571-022-00671-9. Epub 2022 Aug 26.